Clinical trial
A Multicenter, Randomized, Double-Blind, Active-Controlled Trial of the Efficacy and Safety of Adding HSK7653 to Metformin in Chinese Patients With Type 2 Diabetes and Inadequate Glycaemic Control
NCT04564872 is registered in ClinicalTrials.gov with Sichuan Haisco Pharmaceutical Group Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Active-Controlled Trial of the Efficacy and Safety of Adding HSK7653 to Metformin in Chinese Patients With Type 2 Diabetes and Inadequate Glycaemic Control
- Lead sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 13, 2020
- Completion date
- August 29, 2022
- Enrollment
- 465 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.